ClinicalTrials.gg
CompletedNCT04998812MINOREUpdated Apr 15, 2026Results posted

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

A Phase 4 interventional study of Ocrelizumab in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Hoffmann-La Roche. Completed at 11 sites in 5 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
19th of 27
70 · median 170
Started
2022
with 3 others
Phase 4
11 of 27
1 open now
Registered
17th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 19th largest by enrollment, is one of 4 that started in 2022, is one of 11 in phase 4, and was the 17th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

03

Conditions studied

  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Browse trials for

Keywords

  • ocrelizumab, OCREVUS, placental transfer, pregnancy
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MS or CIS (in line with the locally approved indications)
  • Currently pregnant with singleton pregnancy at gestational week ≤30 at enrolment
  • Documentation that first and second obstetric ultrasound has been conducted before enrolment during the screening period
  • Documentation that the last exposure to ocrelizumab occurred up to 6 months before the LMP before the woman became pregnant OR during the first trimester of pregnancy

Exclusion criteria

Exclusion Criteria:

  • Last exposure to ocrelizumab >6 months before the woman's LMP or later than the first trimester of pregnancy
  • Gestational age at enrolment >30 weeks
  • Non-singleton pregnancy
  • Received the last dose of ocrelizumab at a different posology other than per the local prescribing information
  • Lack of access to ultrasound pre-natal care as part of standard clinical practice
  • Prior or current obstetric/gynecological conditions associated with adverse pregnancy outcomes
  • Pre-pregnancy >35 kg/m2
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • Prior or current history of primary or secondary immunodeficiency, or woman in an otherwise severely immunocompromised state
  • Significant and uncontrolled disease that may preclude a woman from participating in the study
  • Women with known active or being actively monitored for recurrence of malignancy including solid tumors and hematological malignancies
  • Prior or current history of alcohol or drug abuse, or current use of tobacco
  • Positive screening tests for
  • Treatment with drugs known to have teratogenic effects
  • Planned treatment with interferons, glatiramer acetate, or pulsed corticosteroids as a bridging therapy after the last ocrelizumab dose and throughout pregnancy
  • Treatment with disease-modifying therapies for MS within their respective half-lives prior to the last ocrelizumab dose or prior to the LMP
  • Treatment with natalizumab within 12 weeks prior to the LMP
  • Treatment with teriflunomide within the last two years, unless measured plasma concentrations are \<0.02 mg/L. If levels are >0.02 mg/L or not known, an accelerated elimination procedure is required
  • Treatment with any agent within 6 months or five half-lives of the investigational drug prior to the last ocrelizumab dose or prior to the LMP
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Pregnant Women with CIS or MS

    Pregnant women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.

    Drug: Ocrelizumab

  • No intervention
    Infants

    Infants born to women receiving commercial ocrelizumab IV either 0-6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13) due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice were observed up to month 13 of age.

Interventions

  • Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.

06

What researchers measure

Primary outcomes

  1. Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)

    The event rate (percentage of infants with B cell levels below LLN) and corresponding Clopper Pearson 95% CI were reported. B-cell reference ranges by week of life (absolute counts) are defined by Borriello et al. 2022.

    Time frame: At Week 6 of infant's life

Secondary outcomes

  1. Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy

    Time frame: At Week 6 of infant's life

  2. Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy

    Time frame: At Week 6 of infant's life

  3. Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth

    Serum ocrelizumab concentrations were measured in the umbilical cord blood at birth (within 1 hour after delivery) to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. At delivery, blood samples from the umbilical cord were collected. Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.

    Time frame: Within 1 hour after delivery (at birth, Day 1)

  4. Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life

    Serum ocrelizumab concentrations were measured were measured at 6 weeks of the infants life to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. Serum samples from the infant were collected.

    Time frame: At Week 6 of infant's life

  5. Serum Concentration of Ocrelizumab in the Mother

    Serum concentration of ocrelizumab in the mother during pregnancy (time frame of blood sampling: Week 24-30, Week 35) and at delivery (time frame of blood sampling: within 24 hours after delivery). Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.

    Time frame: Baseline (gestational Weeks 24-30), gestational Week 35, and at delivery (within 24 hours after delivery) (at birth, Day 1)

  6. Percentage of Infants With Adverse Events

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.

    Time frame: Up to approximately 71 weeks

  7. Percentage of Mothers With Adverse Events

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.

    Time frame: Up to approximately 87.6 weeks

  8. Infant Characteristics at Birth: Body Weight

    Day 1 refers to the time an infant's birth.

    Time frame: At birth (Day 1)

  9. Infant Characteristics at Birth: Head Circumference

    Day 1 refers to the time an infant's birth.

    Time frame: At birth (Day 1)

  10. Infant Characteristics at Birth: Body Length

    Day 1 refers to the time an infant's birth.

    Time frame: At birth (Day 1)

  11. Percentage of Pregnancies Resulting in Live Births, Therapeutic Abortions, or Stillbirth

    Pregnancy outcomes analysed included live births (term and preterm, presence of congenital anomalies) and elective/therapeutic abortions and stillbirths.

    Time frame: During pregnancy (anytime between 37 to 42 weeks of gestation) and at birth (at Day 1)

  12. Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination

    The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  13. Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination

    The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  14. Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination

    The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  15. Percentage of Infants With Positive Humoral Response to MMR Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) are presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 U/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL. Percentages have been rounded off.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  16. Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination

    The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  17. Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination

    The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  18. Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination

    The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  19. Percentage of Infants With Positive Humoral Response to DTP Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for DTP vaccine are as follows: Anti-Diphtheria IgG(-70)CL and Anti-Tetanus Toxoid IgG(-70)RUO: ≥ 0.01 IU/mL; Bordetella pertussis antibodies, IgG: \> 1.04 COI. COI = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO international units for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  20. Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination

    The immune response to Hib vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  21. Percentage of Infants With Positive Humoral Response to Hib Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) will be presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  22. Mean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination

    The immune response to HBV vaccination will be assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine is not planned to be administered. This is to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  23. Percentage of Infants With Positive Humoral Response to HBV Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  24. Mean Titers of Antibody Immune Responses to 13-valent Pneumococcal Conjugate (PCV-13) Vaccination

    The immune response to PCV-13 vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  25. Percentage of Infants With Positive Humoral Response to PCV-13 Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml. Percentages have been rounded off.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

07

Results

Posted May 22, 2025

Participant flow

35 pregnant women (with singleton pregnancy) were enrolled in the study across 10 centers in the United States, Germany, France, Switzerland and Spain from 13 April 2022 to 14 July 2025. An Informed Consent Form (ICF) for participation of the maternal subject and her unborn was signed and dated by the subject. Where applicable, the written ICF with respect to the infant was also signed and dated by the holder of parental rights as designated by the maternal subject.

Pregnancy and Early Post-Partum Period
Participant flow — Pregnancy and Early Post-Partum Period
MilestoneWomenInfants
Started3535
Subject gave birth/infant was born3535
Completed3334
Not completed21
Withdrew: Participant switches to another treatment of ms10
Withdrew: Reason not specified11
Vaccination Period
Participant flow — Vaccination Period
MilestoneWomenInfants
Started3334
Completed3233
Not completed11
Withdrew: Reason not specified11

Outcome measures

PrimaryPercentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)

The event rate (percentage of infants with B cell levels below LLN) and corresponding Clopper Pearson 95% CI were reported. B-cell reference ranges by week of life (absolute counts) are defined by Borriello et al. 2022.

Time frame:
At Week 6 of infant's life
Reported as:
Number · percentage of participants
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)
percentage of participantsInfants
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)0 (0 to 10.28)
SecondaryAbsolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
Time frame:
At Week 6 of infant's life
Reported as:
Median · cells per microliter (cells/µL)
Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
cells per microliter (cells/µL)Infants
Absolute CD19+ B Cell Count in the Infant Potentially Exposed to Ocrelizumab During Pregnancy1170.00 (269.0 to 2408.0)
SecondaryPercentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
Time frame:
At Week 6 of infant's life
Reported as:
Median · percentage of cells
Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy
percentage of cellsInfants
Percentage of CD19+ B Cell in the Infant Potentially Exposed to Ocrelizumab During Pregnancy19.20 (5.2 to 35.3)
SecondarySerum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth

Serum ocrelizumab concentrations were measured in the umbilical cord blood at birth (within 1 hour after delivery) to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. At delivery, blood samples from the umbilical cord were collected. Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.

Time frame:
Within 1 hour after delivery (at birth, Day 1)
Reported as:
Median · nanograms/milliliter (ng/mL)
Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth
nanograms/milliliter (ng/mL)Infants
Serum Concentration of Ocrelizumab in the Umbilical Cord Blood at Birth0.00 (0.0 to 694.0)
SecondarySerum Concentration of Ocrelizumab in the Infant at Week 6 of Life

Serum ocrelizumab concentrations were measured were measured at 6 weeks of the infants life to evaluate whether there was placental transfer of ocrelizumab from the mother to the infant. Serum samples from the infant were collected.

Time frame:
At Week 6 of infant's life
Reported as:
Median · ng/mL
Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life
ng/mLInfants
Serum Concentration of Ocrelizumab in the Infant at Week 6 of Life0.00 (0.0 to 263.0)
SecondarySerum Concentration of Ocrelizumab in the Mother

Serum concentration of ocrelizumab in the mother during pregnancy (time frame of blood sampling: Week 24-30, Week 35) and at delivery (time frame of blood sampling: within 24 hours after delivery). Ocrelizumab serum concentration below the lower limit of quantification (LLOQ = 156 ng/ml) was set to zero.

Time frame:
Baseline (gestational Weeks 24-30), gestational Week 35, and at delivery (within 24 hours after delivery) (at birth, Day 1)
Reported as:
Median · ng/mL
Serum Concentration of Ocrelizumab in the Mother
ng/mLWomen
Baseline - Gestational Weeks 24-300.00 (0.0 to 9090.0)
Gestational Week 350.00 (0.0 to 787.0)
At Delivery0.00 (0.0 to 382.0)
SecondaryPercentage of Infants With Adverse Events

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.

Time frame:
Up to approximately 71 weeks
Reported as:
Number · percentage of infants
Percentage of Infants With Adverse Events
percentage of infantsInfants
Percentage of Infants With Adverse Events82.9
SecondaryPercentage of Mothers With Adverse Events

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Percentages have been rounded off.

Time frame:
Up to approximately 87.6 weeks
Reported as:
Number · percentage of mothers
Percentage of Mothers With Adverse Events
percentage of mothersWomen
Percentage of Mothers With Adverse Events94.3
SecondaryInfant Characteristics at Birth: Body Weight

Day 1 refers to the time an infant's birth.

Time frame:
At birth (Day 1)
Reported as:
Mean · kilogram (kg)
Infant Characteristics at Birth: Body Weight
kilogram (kg)Infants
Infant Characteristics at Birth: Body Weight3.46 ± 0.43
SecondaryInfant Characteristics at Birth: Head Circumference

Day 1 refers to the time an infant's birth.

Time frame:
At birth (Day 1)
Reported as:
Mean · centimeter (cm)
Infant Characteristics at Birth: Head Circumference
centimeter (cm)Infants
Infant Characteristics at Birth: Head Circumference35.08 ± 1.15
SecondaryInfant Characteristics at Birth: Body Length

Day 1 refers to the time an infant's birth.

Time frame:
At birth (Day 1)
Reported as:
Mean · cm
Infant Characteristics at Birth: Body Length
cmInfants
Infant Characteristics at Birth: Body Length51.58 ± 2.15
SecondaryPercentage of Pregnancies Resulting in Live Births, Therapeutic Abortions, or Stillbirth

Pregnancy outcomes analysed included live births (term and preterm, presence of congenital anomalies) and elective/therapeutic abortions and stillbirths.

Time frame:
During pregnancy (anytime between 37 to 42 weeks of gestation) and at birth (at Day 1)
Reported as:
Number · percentage of pregnancies
Percentage of Pregnancies Resulting in Live Births, Therapeutic Abortions, or Stillbirth
percentage of pregnanciesWomen
Live Births100
Congenital Anomalies8.6
Therapeutic Abortions0
Stillbirth0
Preterm0
SecondaryMean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination

The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · mIU/mL
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination
mIU/mLInfants
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to MMR Vaccination2697.43 ± 2124.74
SecondaryMean Titers of Mumps, IgG Antibody in Response to MMR Vaccination

The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · RU/mL
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination
RU/mLInfants
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination94.37 ± 62.56
SecondaryMean Titers of Rubella, IgG Antibody in Response to MMR Vaccination

The immune response to MMR vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination
IU/mLInfants
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination137.57 ± 96.30
SecondaryPercentage of Infants With Positive Humoral Response to MMR Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) are presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 U/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL. Percentages have been rounded off.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to MMR Vaccination
percentage of infantsInfants
Measles, IgG96.4
Mumps, IgG90.0
Rubella, IgG96.3
SecondaryMean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination

The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination
IU/mLInfants
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccination1.02 ± 1.35
SecondaryMean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination

The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · COI
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination
COIInfants
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccination1.45 ± 1.12
SecondaryMean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination

The immune response to DTP vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination
IU/mLInfants
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccination4.34 ± 5.27
SecondaryPercentage of Infants With Positive Humoral Response to DTP Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for DTP vaccine are as follows: Anti-Diphtheria IgG(-70)CL and Anti-Tetanus Toxoid IgG(-70)RUO: ≥ 0.01 IU/mL; Bordetella pertussis antibodies, IgG: \> 1.04 COI. COI = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative; * COI 0.95-1.04: Equivocal; * COI \> 1.04: Positive. The assay used has not been standardized against WHO international units for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to DTP Vaccination
percentage of infantsInfants
Corynebacterium Diphtheriae, IgG100
Bordetella Pertussis, IgG58.6
Clostridium Tetani Toxoid, IgG100
SecondaryMean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination

The immune response to Hib vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · microgram per milliliter (ug/mL)
Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination
microgram per milliliter (ug/mL)Infants
Mean Titers of Antibody Immune Responses to Haemophilus Influenzae Type B (Hib) Vaccination2.99 ± 3.55
SecondaryPercentage of Infants With Positive Humoral Response to Hib Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) will be presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to Hib Vaccination
percentage of infantsInfants
Percentage of Infants With Positive Humoral Response to Hib Vaccination82.8
SecondaryMean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination

The immune response to HBV vaccination will be assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine is not planned to be administered. This is to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · mIU/mL
Mean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination
mIU/mLInfants
Mean Titers of Antibody Immune Responses to Hepatitis B Virus (HBV) Vaccination2101.83 ± 3166.80
SecondaryPercentage of Infants With Positive Humoral Response to HBV Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to HBV Vaccination
percentage of infantsInfants
Percentage of Infants With Positive Humoral Response to HBV Vaccination94.7
SecondaryMean Titers of Antibody Immune Responses to 13-valent Pneumococcal Conjugate (PCV-13) Vaccination

The immune response to PCV-13 vaccination was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · ug/mL
Mean Titers of Antibody Immune Responses to 13-valent Pneumococcal Conjugate (PCV-13) Vaccination
ug/mLInfants
Pneumococcal Capsular Polysaccharide, Serotype 1, IgG3.63 ± 9.40
Pneumococcal Capsular Polysaccharide, Serotype 14, IgG5.89 ± 5.77
Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG3.29 ± 5.15
Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG1.33 ± 2.63
Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG14.01 ± 33.90
Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG4.77 ± 7.62
Pneumococcal Capsular Polysaccharide, Serotype 3, IgG1.92 ± 3.41
Pneumococcal Capsular Polysaccharide, Serotype 4, IgG3.48 ± 8.18
Pneumococcal Capsular Polysaccharide, Serotype 5, IgG3.23 ± 7.32
Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG10.42 ± 19.67
Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG5.51 ± 7.69
Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG3.06 ± 3.44
Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG2.19 ± 3.71
SecondaryPercentage of Infants With Positive Humoral Response to PCV-13 Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml. Percentages have been rounded off.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to PCV-13 Vaccination
percentage of infantsInfants
Pneumococcal Capsular Polysaccharide, Serotype 1, IgG74.1
Pneumococcal Capsular Polysaccharide, Serotype 14, IgG96.3
Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG77.8
Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG51.9
Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG92.6
Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG85.2
Pneumococcal Capsular Polysaccharide, Serotype 3, IgG59.3
Pneumococcal Capsular Polysaccharide, Serotype 4, IgG77.8
Pneumococcal Capsular Polysaccharide, Serotype 5, IgG70.4
Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG92.6
Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG88.9
Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG85.2
Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG74.1

Adverse events

Collected over Infants: Up to approximately 71 weeks Mothers: Up to approximately 87.6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Women0/35 (0%)6/35 (17.1%)28/35 (80%)
Infant0/35 (0%)3/35 (8.6%)26/35 (74.3%)
Most frequent serious events
Most frequent serious events
EventWomenInfant
Premature separation of placentaPregnancy, puerperium and perinatal conditions2/350/35
Neonatal respiratory failureRespiratory, thoracic and mediastinal disorders0/352/35
Cholecystitis acuteHepatobiliary disorders1/350/35
Neonatal infectionInfections and infestations0/351/35
Post procedural infectionInfections and infestations1/350/35
Respiratory syncytial virus infectionInfections and infestations0/351/35
Postpartum haemorrhagePregnancy, puerperium and perinatal conditions1/350/35
Uterine inflammationReproductive system and breast disorders1/350/35
Most frequent other events
Showing 10 of 38
Most frequent other events
EventWomenInfant
COVID-19Infections and infestations8/356/35
Ear infectionInfections and infestations0/357/35
NasopharyngitisInfections and infestations4/357/35
Infusion related reactionInjury, poisoning and procedural complications7/350/35
ConjunctivitisInfections and infestations3/356/35
DiarrhoeaGastrointestinal disorders0/355/35
PyrexiaGeneral disorders1/355/35
BronchitisInfections and infestations0/355/35
Iron deficiencyMetabolism and nutrition disorders5/350/35
CoughRespiratory, thoracic and mediastinal disorders4/354/35

Baseline characteristics

Full analysis set women (FASW) included all enrolled pregnant women who were exposed to ocrelizumab either 0-6 months before the LMP or in the first trimester of pregnancy. Full analysis set infants (FASI) included all infants born to women in the FASW who were potentially exposed to ocrelizumab during pregnancy. As consent for race and ethnicity was not obtained, this data has not been reported.

Age, Customized
Age, Customized(Participants)WomenInfantsTotal
Preterm newborn infants (gestational age <37 weeks)000
Newborns (0-27 days)03535
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)35035
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)WomenInfantsTotal
Female352257
Male01313
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)WomenInfantsTotal
Not reported353570
08

Study locations

11 sites
  • University of California San Francisco
    San Francisco, California 94158, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • The Ken and Ruth Davee department of Neurology
    Chicago, Illinois 60611-4296, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hopital Pierre Wertheimer - Hopital Neurologique
    Bron, 69003, France
  • Hôpital de la Pitié Salpétrière
    Paris, 75013, France
  • St. Josef Hospital GmbH
    Bochum, 44791, Germany
  • MultipEL Studies - Institut für klinische Studien
    Hamburg, 22179, Germany
  • Hosp. Clinico San Carlos
    Madrid, 28040, Spain
  • Universitätsspital Basel
    Basel, 4031, Switzerland
  • Inselspital Bern
    Bern, 3010, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Apr 2024, 23 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 23 months is below that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 10, 2021
StartActual
Apr 13, 2022
Primary completionActual
Apr 8, 2024
CompletionActual
Jul 14, 2025
Results first posted
May 22, 2025
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04998812
Lead sponsor
Hoffmann-La Roche
Collaborators
PPD Development, LP, Laboratory Corporation of America, Illingworth Research Group
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Apr 13, 2022
Primary completion
Apr 8, 2024
Completion
Jul 14, 2025
Results posted
May 22, 2025
Last update
Apr 15, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion